Serum CagA and VacA antibodies and risk for peptic ulcer disease in subjects with Helicobacter pylori infection;Anticuerpos frente a las citotoxinas CagA y VacA y riesgo de úlcera péptica en pacientes con infección por Helicobacter pylori

Medicina Clinica

Volumn 116, Issue 17, 2001, Pages 641-644

  Santolaria, Santos ^a,b   Lanas, Angel ^a   Benito, Rafael ^a   Piazuelo, Elena ^a   Sáinz, Ricardo ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

Author keywords

CagA; Helicobacter pylori; Non steroidal antiinflammatory drugs; Peptic ulcer; VacA

Indexed keywords

ANTIBODY; CAGA ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VACA ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; REGRESSION ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; ULCEROGENESIS;

EID: 0008428701     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71935-5     Document Type: Article

References (28)

1. Santolaria S, Lanas A, Benito B, Pérez-Aisa MA, Montoro M, Sáinz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users: a case-control study. Aliment Pharmacol Ther 1999; 13: 1511-1518.
2. Sipponen R, Varis K, Fraki O, Korri UM, Seppälä K, Siurala M. Cumulative 10 yr. Risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. Scand J Gastroenterol 1990: 25: 966-973.
3. Van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schreeberger P, De Boer W et al Clinical relevance of the CagA, VacA, and IceA status of Helicobacter pylori. Gastroenterology 1998. 115: 58-66.
4. Atherton JC. The clinical relevance of strain types of Helicobacter pylori. Gut 1997; 40: 701-703
5. Atherton JC, Peek RMJ, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in VacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112: 92-99.
6. Miehlke S, Go MF, Kim JG, Graham DY, Figura N. Serologic detection of Helicobacter pylori infection with CagA-positive strains in duodenal ulcer, gastric cancer, and asymptomatic gastritis. J Gastroenterol 1998; 33 (Supl 10): 18-21.
7. Spechler SJ, Fischbach L, Feldman M. Clinical aspects of genetic variability in Helicobacter pylori. JAMA 2000; 283: 1264-1266.
8. Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type 1-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-14653.
9. Atherton JC. CagA: a role at last. Gut 2000; 47: 330-331.
10. + Helicobacter pylori strains. J Clin Microbiol 1995; 33: 1496-1500.
11. Ching CK, Wong BCY, Kwok E, Ong L, Covacci A, Lam SK. Prevalence of CagA-bearing Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls. Am J Gastroenterol 1996; 91: 949-953.
12. Wong BC, Lam SK, Ching CK, Hu WH, Ong LY, Chen BW et al. Seroprevalence of cytotoxin-associated gene A positive Helicobacter pylori strains in Changle, an area with very high prevalence of gastric cancer in South China. Aliment Pharmacol Ther 1999; 13: 1295-1302
13. Mitchell HM, Hazell SL. Li YY, Hu PJ. Serological response to specific Helicobacter pylori antigens. Am J Gastroenterol 1996; 91: 1785-1788.
14. Martín Guerrero JM, Hergueta Delgado P, Esteban Carretero J, Romero Castro R, Pellicer Bautista FJ, Herrerías Gutiérrez JM. Clinical relevance of Helicobacter pylori CagA-positive strains: gastroduodenalpeptic lesions marker. Rev Esp Enferm Dig 2000; 92: 160-173.
15. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992; 267: 10570-10575.
16. Cover TL, Cao P, Lind CD, Tham K, Blaser MJ. Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo. Infect Immun 1993; 61: 5008-5012.
17. Gisbert JP, Blanco M, Mateos JM, Fernández-Salazar L, Fernández-Bermejo M, Cantero J et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999; 4: 2295-2302.
18. Boixeda D, Gisbert JP, Canton R, Álvarez Baleriola I, Bermejo F, Aller R et al. Helicobacter pylori, gastric ulcer and non-steroidal anti-inflammatory agents. Med Clin (Barc) 1996; 106: 209-212.
19. Graham DY, Lidsky MD, Cox AM, Evans DJ, Evans DG, Alpert L et al. Long term non-steroidal anti-inflammatory drug use and Helicobacter infection. Gastroenterology 1991; 100: 1653-1657.
20. Hawkey CJ, Tullasay Z, Szczapanski L, Van Resenburg CJ, Filipowicz A, Lanas A et al. Helicobacter pylori erradication in patients taking non-steroidal antiinflamatory drugs: The HELP NSAIDs study. Lancet 1998; 352: 1016-1021.
21. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of H. pylori infection in healing and recurrence of gastric and duodenal ulcer in long-term NSAID users. Response to omeprazole dual therapy. Gut 1996; 39: 22-26.
22. Yeomans N, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719-726.
23. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-734.
24. Stack WA, Hawkey GM, Atherton JC, Logan RF, Hawkey CJ. Interaction of risk factors for peptic ulcer bleeding. Gastroenterology 1999; 116: A97.
25. Bodger K, Wyatt JI, Heatley RV. Serologic screening before endoscopy: the value of Helicobacter pylori serology, serum recognition of the CagA and VacA proteins, and serum pepsinogen I. Scand J Gastroenterol 1999; 34: 856-863.
26. Rokkas T, Liatsos C, Karameris A, Petridou E, Papatheodorou G, Kalafatis E. Serologic detection of CagA positive Helicobacter pylori strains predicts the presence of peptic ulcer in young dyspeptic patients. Gastrointest Endosc 1999; 50: 511-515.
27. Maeda S, Ogura K, Yoshida H, Kanai F, Ikenoue T, Kato N et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut 1998; 42: 338-343.
28. Shimoyama T, Fukuda S, Tanaka M, Mikami T, Saito Y, Munakata A. High prevalence of the CagA-positive Helicobacter pylori strains in Japanese asymptomatic patients and gastric cancer patients. Scand J Gastroenterol 1997; 32: 465-468.